Bfsg LLC increased its holdings in shares of Stryker Co. (NYSE:SYK) by 1.3% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,881 shares of the medical technology company’s stock after buying an additional 170 shares during the quarter. Bfsg LLC’s holdings in Stryker were worth $2,544,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also made changes to their positions in SYK. Oregon Public Employees Retirement Fund grew its stake in Stryker by 8,029.5% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 6,075,473 shares of the medical technology company’s stock valued at $39,000 after purchasing an additional 6,000,739 shares during the last quarter. Norges Bank purchased a new stake in Stryker during the 4th quarter valued at about $474,132,000. BlackRock Inc. grew its stake in Stryker by 4.1% during the 4th quarter. BlackRock Inc. now owns 24,882,912 shares of the medical technology company’s stock valued at $3,900,399,000 after purchasing an additional 975,678 shares during the last quarter. GQG Partners LLC purchased a new stake in Stryker during the 4th quarter valued at about $116,175,000. Finally, FMR LLC grew its stake in Stryker by 6.3% during the 4th quarter. FMR LLC now owns 5,934,622 shares of the medical technology company’s stock valued at $930,251,000 after purchasing an additional 353,028 shares during the last quarter. Hedge funds and other institutional investors own 74.61% of the company’s stock.
SYK has been the topic of several research analyst reports. BTIG Research boosted their price target on Stryker to $211.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Evercore ISI upgraded Stryker from an “in-line” rating to an “outperform” rating and set a $156.75 price target on the stock in a research note on Wednesday, January 2nd. Piper Jaffray Companies reiterated an “overweight” rating and set a $205.00 price target on shares of Stryker in a research note on Friday, March 1st. Morgan Stanley dropped their price target on Stryker from $212.00 to $197.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 2nd. Finally, SunTrust Banks boosted their price target on Stryker to $205.00 and gave the company a “positive” rating in a research note on Monday, February 4th. Nine investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Stryker currently has a consensus rating of “Buy” and an average price target of $192.13.
In related news, VP Katherine Ann Owen sold 29,247 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $185.62, for a total value of $5,428,828.14. Following the completion of the transaction, the vice president now owns 11,131 shares of the company’s stock, valued at approximately $2,066,136.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Chairman Kevin Lobo sold 41,750 shares of the company’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $194.11, for a total value of $8,104,092.50. The disclosure for this sale can be found here. In the last three months, insiders sold 130,455 shares of company stock valued at $24,723,292. Insiders own 7.20% of the company’s stock.
Shares of SYK stock opened at $180.26 on Friday. The stock has a market capitalization of $67.26 billion, a PE ratio of 24.66, a P/E/G ratio of 2.38 and a beta of 0.88. The company has a quick ratio of 1.41, a current ratio of 2.02 and a debt-to-equity ratio of 0.72. Stryker Co. has a 52-week low of $144.75 and a 52-week high of $199.85.
Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 29th. The medical technology company reported $2.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.15 by $0.03. The business had revenue of $3.80 billion during the quarter, compared to analysts’ expectations of $3.73 billion. Stryker had a return on equity of 27.60% and a net margin of 26.12%. As a group, equities research analysts expect that Stryker Co. will post 8.13 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 30th. Stockholders of record on Friday, March 29th will be issued a $0.52 dividend. The ex-dividend date is Thursday, March 28th. This represents a $2.08 annualized dividend and a dividend yield of 1.15%. Stryker’s dividend payout ratio (DPR) is presently 28.45%.
TRADEMARK VIOLATION NOTICE: “Stryker Co. (SYK) Shares Bought by Bfsg LLC” was first reported by Highlight Press and is the sole property of of Highlight Press. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://highlightpress.com/2019/04/20/stryker-co-syk-shares-bought-by-bfsg-llc.html.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Recommended Story: What does cost of debt say about a company’s financial health?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.